TORONTO, Jan. 10, 2013 /CNW/ - Microbix Biosystems Inc.
(TSX:MBX) today refiled its financial statements for the year ended
September 30, 2012 to correct two
oversights in the Consolidated Statements of Comprehensive
Loss.
The previously filed Consolidated Statements of Comprehensive
Loss had properly reported total revenue, total expenses, and net
loss per share. However, the cost of goods sold reported for
Virology products and technologies was misstated and should have
read $3,807,360 rather than
$2,502,288 for the year ending
September 30, 2012, and $2,795,310 rather than $1,298,672 for the year ending September 30, 2011. Also, the
International Financial Reporting Standards adjustments for the
year ended September 30, 2011 was
misstated as $5,391,611 and should
have read $5,598,445. All
other information contained in the previously filed financial
statements for the year ended September 30,
2012 remains unchanged.
The refilled annual financial statements are available at
www.SEDAR.com.
The Toronto Stock Exchange does not accept responsibility for
the adequacy or accuracy of this release.
About Microbix Biosystems Inc.
Microbix Biosystems Inc. specializes in the development of the
most advanced vaccine production technology and markets virology
and biological products worldwide. In addition, The Company has
intellectual property in large market biotherapeutic drugs, vaccine
technologies and animal reproduction technologies. Microbix
supplies customers in the U.S., Europe, and Asia. Established in 1988, Microbix is
headquartered in Toronto.
SOURCE Microbix Biosystems Inc.
